Australia's largest stock trading and investment forum Australia's #1 stock forum

WFL

Click for more information

0.00%

0.3¢ wellfully limited

If any one is interested in purchasing this report, it would be...

First 186 Last

Share
Profile

Follow
Third Eye

1,066 Posts.

663

22/01/15

13:47

Post #: 14623642
Share

Originally posted by makattack ↑

Isn't a comms strategy about raising awareness of the company and its products/affiliations?

Depends what the strategy is. OBJ have never been really strong on publicising their progress to investors but have improved a lot in recent times. Whether that is good or bad is debatable but I do know that there is often a strong correlation between number of capital raisings and number of announcements, particularly in the speculative end of town. As you may know over the last few years, OBJ have only had 1 placement. So I am comfortable with OBJ highlighting in announcements the really important things to help highlight them than inundate us with announcement after announcement. For me, results are the most important and I have no grievances with their successes thus far.

Expand

If any one is interested in purchasing this report, it would be great to see some projections other than the Bakers report;

http://www.bioportfolio.net/report/50745-obj-limited-obj-financial-and-strategic.html

OBJ Price at posting: 9.2¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

HotCopper Highlights: Your most watched stocks for Week 46, 2024

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

First 186 Last

Add WFL (ASX) to my watchlist

SPONSORED BY